These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37901832)

  • 21. MRI-Based Radiomic Models Outperform Radiologists in Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
    Wen L; Liu J; Hu P; Bi F; Liu S; Jian L; Zhu S; Nie S; Cao F; Lu Q; Yu X; Liu K
    Acad Radiol; 2023 Sep; 30 Suppl 1():S176-S184. PubMed ID: 36739228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The value of MR T2WI signal intensity related parameters for predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer].
    Wan LJ; Zhang CD; Zhang HM; Meng YK; Ye F; Liu Y; Zhao XM; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):837-843. PubMed ID: 31770851
    [No Abstract]   [Full Text] [Related]  

  • 23. Pretreatment blood biomarkers combined with magnetic resonance imaging predict responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Shi X; Zhao M; Shi B; Chen G; Yao H; Chen J; Wan D; Gu W; He S
    Front Oncol; 2022; 12():916840. PubMed ID: 36016621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of the Prediction Model for Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy Based on Pretreatment Tumor-Infiltrating Macrophage-Associated Biomarkers.
    Liu X; Zheng S; Peng Y; Zhuang J; Yang Y; Xu Y; Guan G
    Onco Targets Ther; 2021; 14():2599-2610. PubMed ID: 33880038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep Learning Model for Predicting the Pathological Complete Response to Neoadjuvant Chemoradiotherapy of Locally Advanced Rectal Cancer.
    Lou X; Zhou N; Feng L; Li Z; Fang Y; Fan X; Ling Y; Liu H; Zou X; Wang J; Huang J; Yun J; Yao J; Huang Y
    Front Oncol; 2022; 12():807264. PubMed ID: 35756653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil.
    D'Angelo E; Pastrello C; Biccari A; Marangio A; Sensi F; Crotti S; Fassan M; Jurisica I; Pucciarelli S; Agostini M
    Int J Cancer; 2023 Jul; 153(2):437-449. PubMed ID: 36815540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of glucocorticoids on the efficacy of neoadjuvant chemoradiotherapy and survival of patients with locally advanced rectal cancer: a retrospective study.
    Huang X; Zheng Z; Zeng B; Xiao H; Zheng H; Lin Z; Song J; Li A; Chi P; Yang Y; Xu B; Zheng R
    BMC Cancer; 2023 Mar; 23(1):238. PubMed ID: 36918865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    Yang Y; Tian W; Su L; Li P; Gong X; Shi L; Zhang Q; Zhao B; Zhao H
    Front Oncol; 2021; 11():743540. PubMed ID: 34733785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3.0 T MRI IVIM-DWI for predicting the efficacy of neoadjuvant chemoradiation for locally advanced rectal cancer.
    Hu H; Jiang H; Wang S; Jiang H; Zhao S; Pan W
    Abdom Radiol (NY); 2021 Jan; 46(1):134-143. PubMed ID: 32462386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
    Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
    Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study.
    Yi Y; Shen L; Shi W; Xia F; Zhang H; Wang Y; Zhang J; Wang Y; Sun X; Zhang Z; Zou W; Yang W; Zhang L; Zhu J; Goel A; Ma Y; Zhang Z
    Clin Cancer Res; 2021 Mar; 27(5):1329-1340. PubMed ID: 33298472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
    Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker.
    Kim S; Yeo MK; Kim JS; Kim JY; Kim KH
    J Cancer; 2022; 13(1):162-173. PubMed ID: 34976180
    [No Abstract]   [Full Text] [Related]  

  • 36. Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer.
    Lopes-Ramos C; Koyama FC; Habr-Gama A; Salim AC; Bettoni F; Asprino PF; França GS; Gama-Rodrigues J; Parmigiani RB; Perez RO; Galante PA; Camargo AA
    Cancer Genet; 2015 Jun; 208(6):319-26. PubMed ID: 25963525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.
    Jia H; Shen X; Guan Y; Xu M; Tu J; Mo M; Xie L; Yuan J; Zhang Z; Cai S; Zhu J; Zhu Z
    Radiother Oncol; 2018 Sep; 128(3):548-556. PubMed ID: 30041962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI-based delta-radiomics are predictive of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Wan L; Peng W; Zou S; Ye F; Geng Y; Ouyang H; Zhao X; Zhang H
    Acad Radiol; 2021 Nov; 28 Suppl 1():S95-S104. PubMed ID: 33189550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative Fibrinogen-Albumin Ratio Index (FARI) is a Reliable Prognosis and Chemoradiotherapy Sensitivity Predictor in Locally Advanced Rectal Cancer Patients Undergoing Radical Surgery Following Neoadjuvant Chemoradiotherapy.
    Lu S; Liu Z; Zhou X; Wang B; Li F; Ma Y; Wang W; Ma J; Wang Y; Wang H; Fu W
    Cancer Manag Res; 2020; 12():8555-8568. PubMed ID: 32982448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Lv T; Shen L; Xu X; Yao Y; Mu P; Zhang H; Wan J; Wang Y; Guan R; Li X; Fu G; Zhang L; Wang Y; Xia F; Hu C; Clevers H; Zhang Z; Hua G
    Int J Cancer; 2023 Feb; 152(3):524-535. PubMed ID: 36161653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.